Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.

Baiz D, Pinder TA, Hassan S, Karpova Y, Salsbury F, Welker ME, Kulik G.

J Med Chem. 2012 Sep 27;55(18):8038-46. Epub 2012 Sep 10.

2.

Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.

O'Brien NJ, Amran S, Medan J, Cleary B, Deady LW, Jennings IG, Thompson PE, Abbott BM.

ChemMedChem. 2013 Jun;8(6):914-8. doi: 10.1002/cmdc.201200583. Epub 2013 Apr 8.

PMID:
23568455
3.

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.

Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.

Prostate. 2004 Feb 15;58(3):259-68.

PMID:
14743465
4.

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL.

Cancer Res. 2008 Jan 1;68(1):206-15. doi: 10.1158/0008-5472.CAN-07-0669. Erratum in: Cancer Res. 2008 Jul 15;68(1):6030.

5.

Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.

Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S.

Int J Cancer. 2007 Oct 1;121(7):1424-32.

6.

Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.

Badinloo M, Esmaeili-Mahani S.

Fundam Clin Pharmacol. 2014 Aug;28(4):414-22. doi: 10.1111/fcp.12043. Epub 2013 Jul 10.

PMID:
23837575
7.

Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.

Bertram J, Peacock JW, Tan C, Mui AL, Chung SW, Gleave ME, Dedhar S, Cox ME, Ong CJ.

Cancer Res. 2006 May 1;66(9):4781-8.

8.

LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.

Li C, Liu VW, Chan DW, Yao KM, Ngan HY.

Int J Gynecol Cancer. 2012 Jan;22(1):15-22. doi: 10.1097/IGC.0b013e3182322834.

PMID:
22080879
10.

MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.

Sarveswaran S, Myers CE, Ghosh J.

Cancer Lett. 2010 May 28;291(2):167-76. doi: 10.1016/j.canlet.2009.10.008. Epub 2009 Nov 10.

PMID:
19906484
11.

Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.

Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L, Chuang KH, Wu CT, Chang C.

J Biol Chem. 2005 Sep 30;280(39):33558-65. Epub 2005 Aug 1.

12.

Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.

Morales GA, Garlich JR, Su J, Peng X, Newblom J, Weber K, Durden DL.

J Med Chem. 2013 Mar 14;56(5):1922-39. doi: 10.1021/jm301522m. Epub 2013 Feb 27.

PMID:
23410005
13.

The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.

Garsky VM, Lumma PK, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, DeFeo-Jones D, Freidinger RM.

J Med Chem. 2001 Nov 22;44(24):4216-24.

PMID:
11708923
14.

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y.

Oncol Rep. 2012 Jun;27(6):1703-9. doi: 10.3892/or.2012.1724. Epub 2012 Mar 15.

PMID:
22426819
15.

1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.

Axanova LS, Chen YQ, McCoy T, Sui G, Cramer SD.

Prostate. 2010 Nov 1;70(15):1658-71. doi: 10.1002/pros.21201.

17.

[Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].

Liu Y, Chen X, Luo Z.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Jun;30(6):592-6. Chinese.

PMID:
24909280
18.
20.

EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.

Hakariya T, Shida Y, Sakai H, Kanetake H, Igawa T.

Biochem Biophys Res Commun. 2006 Mar 31;342(1):92-100. Epub 2006 Feb 2.

PMID:
16472761

Supplemental Content

Support Center